Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria

References

• UNAIDS. Report on the global HIV/AIDS epidemic 2008. Joint United Nations Programme on HIV/AIDS, 2008, Geneva, Switzerland.
   Google Scholar
• UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. UNAIDS, Geneva, Switzerland.
   Google Scholar
• UNAIDS. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Progress report 2011. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
   Google Scholar
• UNAIDS. UNAIDS data tables 2011. Joint United Nations Programme on HIV/AIDS (UNAIDS), 2011, Geneva, Switzerland.
   Google Scholar
• Calmy A, Klement E, Teck R, Berman D, Pecoul B, Ferradini L. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. AIDS. 2004;18:2353–60.
   PubMed Web of Science ®Google Scholar
• Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, et al.. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40:336–43.
   PubMed Web of Science ®Google Scholar
• Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, et al.. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20:41–8.
   PubMed Web of Science ®Google Scholar
• Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
   PubMed Web of Science ®Google Scholar
• Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al.. True outcomes for patients on antiretroviral therapy who are ‘lost to follow-up’ in Malawi. Bulletin of the World Health Organization. 2007;85:550–554.
   PubMed Web of Science ®Google Scholar
• MOH Malawi. ARV therapy in Malawi — up to 31st March 2006. Quarterly report. HIV Unit, Ministry of Health Malawi, 2006, Lilongwe, Malawi.
   Google Scholar
• Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al.. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817–24.
   PubMed Web of Science ®Google Scholar
• Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al.. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335–42.
   PubMed Web of Science ®Google Scholar
• Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20:1163–9.
   PubMed Web of Science ®Google Scholar
• UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Geneva, Switzerland, UNAIDS.
   Google Scholar
• Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, et al.. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative–Uganda. AIDS. 2003;17(Suppl 3), S39–S48.
   Google Scholar
• Poppa A, Davidson O, Deutsch J, Godfrey D, Fisher M, Head S, et al.. British HIV Association (BHIVA)/British Association for Sexual Health and HIV (BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy (2003). HIV Med. 5(Suppl 2), 46–60.
   Google Scholar
• Hanson K, Hicks C. New antiretroviral drugs. Curr HIV/AIDS Rep. 2006;3:93–101.
   Google Scholar
• Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005;5:115–9.
   PubMed Web of Science ®Google Scholar
• Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, et al.. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis. 2005;5:481–93.
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics. Federal Republic of Nigeria: 2006 population census. Abuja, Nigeria, Federal Government of Nigeria, 2006, [cited 07/07/09]. Available at: www.nigerianstat.gov.ng.
   Google Scholar
• Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, M’Bangue M, et al.. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis. 2005;41:108–11.
   Web of Science ®Google Scholar
• Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45:304–10.
   PubMed Web of Science ®Google Scholar
• Kabugo C, Bahendeka S, Mwebaze R, Malamba S, Katuntu D, Downing R, et al.. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr. 2005;38:578–83.
   Web of Science ®Google Scholar
• Tsague L, Koulla SS, Kenfak A, Kouanfack C, Tejiokem M, Abong T, et al.. Determinants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003–2005. Pan African Med J. 2008;1:2.
   PubMedGoogle Scholar
• Taylor-Smith K, Tweya H, Harries A, Schoutene E, Jahn A. Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J. 2010;22:49–56.
   Web of Science ®Google Scholar
• Pacheco AG, Saraceni V, Tuboi SH, Moulton LH, Chaisson RE, Cavalcante SC, et al.. Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in Brazil. Am J Edpidemiol. 2008;168:1326–32.
   PubMed Web of Science ®Google Scholar
• Akesode FA. Registration of births and deaths in Lagos, Nigeria. J Tropl Pediatr. 1980;26:150–5.
   Web of Science ®Google Scholar
• Akande TM, Sekoni OO. A survey of birth and death registration in a semi-urban settlement in middle-belt Nigeria. Eur J Sci Res. 2005;8:56–61.
   Google Scholar
• Onwujekwe O, Dike N, Chukwuka C, Uzochukwu B, Onyedum C, Onoka C, et al.. Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria. Health Policy. 2009;90:223–9.
   PubMed Web of Science ®Google Scholar
• World Bank. Averting a human crisis during the global downturn: policy options from the World Bank’s human development network. Washington, DC, USA, 2009 [cited 18 June 2009]. Available at: http://www.uniteforchildren.org/files/world_bank.pdf (accessed 12 June 2009).
   Google Scholar
• Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. Jf Antimicrob Chemother. 2005;55:413–6.
   PubMed Web of Science ®Google Scholar
• Desvarieux M, Landman R, Liautaud B, Girard PM. Antiretroviral therapy in resource-poor countries: illusions and realities. Am J Public Health. 2005;95:1117–22.
   PubMed Web of Science ®Google Scholar